Lantibiotics and microcins: Polypeptides with unusual chemical diversity

Current Opinion in Chemical Biology

Volumn 4, Issue 3, 2000, Pages 310-317

  Jack, Ralph W ^a,b   Jung, Günther ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b EMC MICROCOLLECTIONS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LANTIBIOTIC; MICROCIN B17; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; BIOTECHNOLOGY; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; ORGANIC CHEMISTRY; REVIEW; STRUCTURE ANALYSIS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0034117808     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00094-6     Document Type: Review

References (58)

1. Mootz H.D., Marahiel M.A. Biosynthetic systems for nonribosomal peptide antibiotic assembly. Curr Opin Chem Biol. 1:1997;543-551.
2. Keating T.A., Walsh C.T. Initiation, elongation, and termination strategies in polyketide and polypeptide antibiotic biosynthesis. Curr Opin Chem Biol. 3:1999;598-606.
3. Mootz H.D., Marahiel M.A. Design and application of multimodular peptide synthetases. Curr Opin Biotechnol. 10:1999;341-348.
4. Konz D., Marahiel M.A. How do peptide synthetases generate structural diversity? Chem Biol. 6:1999;39-48.
5. Jack R.W., Tagg J.R., Ray B. Bacteriocins of Gram-positive bacteria. Microbiol Rev. 59:1995;171-200.
6. Nissen-Meyer J., Nes I.F. Ribosomally synthesized antimicrobial peptides: their function, structure, biogenesis, and mechanism of action. Arch Microbiol. 167:1997;67-77.
7. Schnell N., Entian K.D., Schneider U., Götz F., Zähner H., Kellner R., Jung G. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature. 333:1988;276-278.
8. Jung G Lantibiotics - a survey. Jung G., Sahl H-G. Nisin and Novel Lantibiotics. 1991;1-34 ESCOM, Leiden, The Netherlands.
9. Jung G. Lantibiotics - ribosomally synthesised biologically active polypeptides containing sulphide rings and α,β-didehydroamino acids. Angew Chem Int Ed Engl. 30:1991;1051-1068.
10. Jack R.W., Götz F., Jung G. Lantibiotics. Kleinkauf H., von Döhren H. Biotechnology, edn 2, vol 7. Products of Secondary Metabolism. 1997;232-368 VCH, Weinheim, Germany.
11. Sahl H-G., Jack R.W., Bierbaum G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur J Biochem. 230:1995;827-853.
12. Jack R.W., Bierbaum G., Sahl H-G. Lantibiotics and Related Peptides. 1998;Springer-Verlag, Heidelberg.
13. Sahl H-G., Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from Gram-positive bacteria. Annu Rev Microbiol. 52:1998;41-79.
14. Rogers L.A., Whittier E.O. Limiting factors in lactic fermentation. J Bacteriol. 16:1928;211-214.
15. Delves-Broughton J., Blackburn P., Evans R.J., Hugenholtz J. Applications of the bacteriocin nisin. Antonie van Leeuwenhoek. 69:1996;193-202.
16. Gross E., Morell J.L. The structure of nisin. J Am Chem Soc. 93:1971;4634-4635.
17. Wakamiya T., Fukase K., Sano A., Shimbo K., Kitizawa M., Horimoto S., Fujita H., Kubo A., Maeshiro Y., Shiba T. Studies on chemical synthesis of the lanthionine peptide nisin. Jung G., Sahl H-G. Nisin and Novel Lantibiotics. 1991;189-203 ESCOM, Leiden, The Netherlands.
18. Allgaier H., Jung G., Werner R.G., Schneider U., Zähner H. Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic Eur J Biochem. 160:1986;9-22.
19. Siezen R.J., Kuipers O.P., de Vos W.M. Comparison of lantibiotic gene clusters and encoded proteins. Antonie van Leeuwenhoek. 69:1996;171-184.
20. Kuipers O.P., Bierbaum G., Ottenwälder B., Dodd H.M., Horn N., Metzger J., Kupke T., Gnau V., Bongers R., van den Bogaard P.et al. Protein engineering of lantibiotics. Antonie van Leeuwenhoek. 69:1996;161-169.
21. Bierbaum G., Götz F., Peschel A., Kupke T., van de Kamp M., Sahl H-G. The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K.7. Antonie van Leeuwenhoek. 69:1996;119-127.
22. Meyer C., Bierbaum G., Heidrich C., Reis M., Süling J., Iglesias-Wind M.I., Kempter C., Molitor E., Sahl H-G. Nucleotide sequence of the lantibiotic Pep5 biosynthetic gene cluster and functional analysis of PepP and PepC. Evidence for a role of PepC in thioether formation. Eur J Biochem. 232:1995;478-489.
23. Navaratna M.A., Sahl H-G., Tagg J.R. Two-component anti-Staphylococcus aureus lantibiotic activity produced by Staphylococcus aureus C55. Appl Environ Microbiol. 64:1998;4803-4808.
24. Navaratna M.A., Sahl H-G., Tagg J.R. Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene. Infect Immun. 67:1999;4268-4271. Together with [23], the authors demonstrate that the phenomenon of two-component lantibiotic biosynthesis may well be more widespread than previously thought (at least in the pathogen S. aureus). It remains unclear why these systems have developed and why they should be favoured over single-peptide systems.
25. Ryan M.P., Jack R.W., Josten M., Sahl H-G., Jung G., Ross R.P., Hill C. Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. J Biol Chem. 274:1999;37544-37550. The finding of a further lantibiotic containing D-alanine raises the important question of its biological activity. It may be that these residues are necessary to stabilise essential secondary structure elements, that they are somehow directly involved in the biological activity of the peptide(s), or that their presence provides increased resistance to degradation. To date, analogues devoid of D-alanine have not been reported, although it would be theoretically possible, using site-directed mutagenesis, to introduce L-alanine in place of serine in the prepeptide sequence.
26. Gilmore M.S., Skaugen M., Nes I.F. Enterococcus faecalis cytolysin and lactocin S of Lactobacillus sake. Antonie van Leeuwenhoek. 69:1996;129-138.
27. Booth M.C., Bogie C.P., Sahl H-G., Siezen R.J., Hatter K.L., Gilmore M.S. Structural analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel lantibiotic. Mol Microbiol. 21:1996;1175-1184.
28. Skaugen M., Nissen-Meyer J., Jung G., Stevanovic S., Sletten K., Inger C., Abildgaard M., Nes I.F. In vivo conversion of L-serine to D-alanine in a ribosomally synthesized polypeptide. J Biol Chem. 269:1994;27183-27185.
29. Dougherty B.A., Hill C., Weidman J.F., Richardson D.R., Venter J.C., Ross R.P. Sequence and analysis of the 60 kb conjugative, bacteriocin-producing plasmid pMRC01 from Lactococcus lactis DPC3147. Mol Microbiol. 29:1998;1029-1038.
30. van Kraaij C., Breukink E., Rollema H.S., Bongers R.S., Kosters H.A., de Kruijff B., Kuipers O.P. Engineering a disulfide bond and free thiols in the lantibiotic nisin Z. Eur J Biochem. 267:2000;901-909. The authors provide an important contribution that demonstrates the need to better understand the fine structure and dynamics of the lantibiotics. The introduction of the conformationally less restricted disulfide suggests that Lan has been selected by nature, at least in part, because it offers not only chemical diversity, but also both structural diversity and conformational restriction. Further explanation for the altered biological activity of this analogue is also offered in [34••].
31. Brötz H., Bierbaum G., Reynolds P.E., Sahl H-G. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem. 246:1997;193-199.
32. Brötz H., Bierbaum G., Leopold K., Reynolds P.E., Sahl H-G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother. 42:1998;154-160.
33. Brötz H., Josten M., Wiedemann I., Schneider U., Götz F., Bierbaum G., Sahl H-G. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol. 30:1998;317-327.
34. Breukink E., Wiedemann I., van Kraaij C., Kuipers O.P., Sahl H-G., de Kruijff B. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 286:1999;2361-2364. This important contribution brings together the significant work that has identified lipid II as a 'docking molecule' involved in lantibiotic bioactivity (see also [31-33]). The thrust of the article is to show that nisin (and therefore perhaps other lantibiotics) acts at a variety of levels. Lipid II is able to stabilise the pores formed by nisin; it can also form pores in the absence of the docking molecule, but at much higher concentrations and with considerably less stable pores.
35. Fath M.J., Zhang L.H., Rush J., Kolter R. Purification and characterization of colicin V from Escherichia coli culture supernatants. Biochemistry. 33:1994;6911-6917.
36. Bayer A., Freund S., Nicholson G., Jung G. Post-translational backbone modifications form heteroaromatic five-membered rings during the synthesis of the glycine rich antibiotic microcin B17. Angew Chem Int Ed Engl. 32:1993;1336-1339.
37. 15N-labelled gyrase inhibitor. Eur J Biochem. 234:1995;414-426.
38. Guijarro J.I., Gonzalez-Pastor J.E., Baleux F., San Millan J.L., Castilla M.A., Rico M., Moreno F., Delepierre M. Chemical structure and translation inhibition studies of the antibiotic microcin C7. J Biol Chem. 270:1995;23520-23532.
39. Gonzalez-Pastor J.E., San Millan J.L., Castilla M.A., Moreno F. Structure and organization of plasmid genes required to produce the translation inhibitor microcin C7. J Bacteriol. 177:1995;7131-7140.
40. Blond A., Peduzzi J., Goulard C., Chiuchiolo M.J., Barthelemy M., Prigent Y., Salomon R.A., Farias R.N., Moreno F., Rebuffat S. The cyclic structure of microcin J25, a 21-residue peptide antibiotic from Escherichia coli. Eur J Biochem. 259:1999;747-755.
41. Solbiati J.O., Ciaccio M., Farias R.N., Gonzalez-Pastor J.E., Moreno F., Salomon R.A. Sequence analysis of the four plasmid genes required to produce the circular peptide antibiotic microcin J25. J Bacteriol. 181:1999;2659-2662.
42. Genilloud O., Moreno F., Kolter R. DNA sequence, products, and transcriptional pattern of the genes involved in production of the DNA replication inhibitor microcin B17. J Bacteriol. 71:1989;1126-1135.
43. Videnov G., Kaiser D., Kempter C., Jung G. Synthesis of naturally-occurring, conformationally-restricted oxazole- and thiazole-containing di- and tri-peptides mimetics. Angew Chem Int Ed Engl. 35:1996;1503-1506.
44. Videnov G., Kaiser D., Kempter C., Brooks M., Jung G. Synthesis of the DNA gyrase inhibitor microcin B17, a 43 peptide antibiotic with eight heteroaromatic rings in the backbone. Angew Chem Int Ed Engl. 35:1996;1506-1598.
45. Lewis J.R. Amaryllidaceae, muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids. Nat Prod Rep. 17:2000;57-84.
46. Vizán J.L., Hernández-Chico C., del Castillo I., Moreno F. The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase. EMBO J. 10:1991;467-476.
47. Couturier M., Bahassi el-M., van Melderen L. Bacterial death by DNA gyrase poisoning. Trends Microbiol. 6:1998;269-275.
48. Li Y-M., Milne J.C., Madison L.L., Kolter R., Walsh C.T. From peptide precursors to oxazole and thiazole-containing peptide antibiotics: microcin B17 synthase. Science. 274:1996;1188-1193.
49. Milne J.C., Eliot A.C., Kelleher N.L., Walsh C.T. ATP/GTP hydrolysis is required for oxazole and thiazole biosynthesis in the peptide antibiotic microcin B17. Biochemistry. 37:1998;13250-13261.
50. Milne J.C., Sinha Roy R., Eliot A.C., Kelleher N.L., Wokhlu A., Nickels B., Walsh C.T. Cofactor requirements and reconstitution of microcin B17 synthetase: a multienzyme complex that catalyzes the formation of oxazoles and thiazoles in the antibiotic microcin B17. Biochemistry. 38:1999;4768-4781. A full understanding of the MccB17 synthetase is essential before such complexes could be employed in biotechnological production of novel structures. Moreover, the study of the cofactor requirements of this synthetase (together with [48,49]) provides an important insight into the molecular mechanisms involved in generating chemical and structural diversity in biosynthesised peptides and proteins.
51. Madison L.L., Vivas E.I., Li Y.M., Walsh C.T., Kolter R. The leader peptide is essential for the post-translational modification of the DNA-gyrase inhibitor microcin B17. Mol Microbiol. 23:1997;161-168.
52. Sinha Roy R., Kim S., Baleja J.D., Walsh C.T. Role of the microcin B17 propeptide in substrate recognition: solution structure and mutational analysis of McbA1-26. Chem Biol. 5:1998;217-228.
53. Sinha Roy R., Belshaw P.J., Walsh C.T. Mutational analysis of post-translational heterocycle biosynthesis in the gyrase inhibitor microcin B17: distance dependence from propeptide and tolerance for substitution in a GSCG cyclizable sequence. Biochemistry. 37:1998;4125-4136.
54. Sinha Roy R., Kelleher N.L., Milne J.C., Walsh C.T. In vivo processing and antibiotic activity of microcin B17 analogs with varying ring content and altered bisheterocyclic sites. Chem Biol. 6:1999;305-318. The characterisation of novel MccB17 analogues with altered activity may well point to new lead structures and help to identify pharmacophores. In particular, the bis-heterocycles of MccB17 appear to be of major importance.
55. Stankova I.G., Videnov G.I., Golovinsky E.V., Jung G. Synthesis of thiazole, imidazole and oxazole containing amino acids for peptide backbone modification. J Pept Sci. 5:1999;392-398. Facile methods to approach the synthesis of mimetic structures related to those natural substances described here are needed if combinatorial approaches to new compound design are to be successful. Ozl/Tzl and related structures are logical choices for the investigation of DNA-interacting compounds and offer a new means of restricting conformational freedom and generating additional diversity in peptide mimetics.
56. Belshaw P.J., Sinha Roy R., Kelleher N.L., Walsh C.T. Kinetics and regioselectivity of peptide-to-heterocycle conversions by microcin B17 synthetase. Chem Biol. 5:1998;373-384.
57. •], a relatively complete model for the biosynthesis of MccB17 can finally be envisaged.
58. Sinha Roy R., Allen O., Walsh C.T. Expressed protein ligation to probe regiospecificity of heterocyclization in the peptide antibiotic microcin B17. Chem Biol. 6:1999;789-799. EPL is a relatively new technique allowing the incorporation of, in particular, unusual (i.e. not genetically encoded) amino acids into peptides and proteins in a semi-synthetic manner. The use of EPL to incorporate homocysteine demonstrates the potential of this technique in such studies and shows that the Mccb17 synthetase is reasonably discerning in its choice of substrate. The results fit well with earlier work showing that threonine cannot be substituted in place of serine.